Involvement of the soluble urokinase receptor in chondrosarcoma cell mobilization.
High levels of urokinase receptor (uPAR) in tissue and serum of patients with chondrosarcoma correlate with poor prognosis. First, we analyzed the uPAR levels in tissues and plasma of five patients affected by chondrosarcoma. Interestingly, very high levels of uPAR and its soluble forms (SuPAR) were found on tumor cell surfaces and plasma, respectively, of two patients with lung metastases. Therefore, to investigate the role of SuPAR in chondrosaromas, we generated a primary cell culture from a chondrosarcoma tissue overexpressing uPAR on cell surfaces. We found that chondrosarcoma-like primary culture cells release a large amount of SuPAR in the medium. In vitro, SuPAR elicits chondrosarcoma cell migration likely through its uPAR(88-92) sequence, since the DII(88-183) or DIIDIIR(88-284) uPAR domains retain motogen effect whereas DI(1-87) or DIII(184-284) domains, both lacking the uPAR(88-92) sequence, are ineffective. Chondrosarcoma cells cross matrigel in response to SuPAR, and their invasion capability is abrogated by RERF peptide which inhibits uPAR(88-92) signalling. These findings assign a role to uPAR in mobilizing chondrosarcoma cells and suggest that RERF peptide may be regarded as a prototype to generate new therapeutics for the chondrosarcoma treatment.
Department of Experimental Oncology, National Cancer Institute of Naples, Via Mariano Semmola 1, 80131 Naples, Italy.
Katia
K
Bifulco
Immacolata
I
Longanesi-Cattani
Maria Teresa
MT
Masucci
Annarosaria
A
De Chiara
Flavio
F
Fazioli
Gioconda
G
Di Carluccio
Giuseppe
G
Pirozzi
Michele
M
Gallo
Antonello
A
La Rocca
Gaetano
G
Apice
Gaetano
G
Rocco
Maria Vincenza
MV
Carriero
J Mol Biol. 2006 Oct 20;363(2):482-95
16979660
Oncologist. 2008 Mar;13(3):320-9
18378543
J Bone Joint Surg Br. 2002 Jan;84(1):93-9
11837841
FEBS Lett. 2000 Jun 9;475(1):52-6
10854857
Mol Cancer Ther. 2009 Sep;8(9):2708-17
19706734
Nat Rev Mol Cell Biol. 2010 Jan;11(1):23-36
20027185
Front Biosci. 2008 May 01;13:6752-62
18508692
Thromb Haemost. 2005 Apr;93(4):676-81
15841311
Int J Cancer. 2002 Dec 20;102(6):562-71
12447996
Clin Cancer Res. 2008 Sep 15;14(18):5785-93
18794088
Cancer Res. 2006 Nov 15;66(22):10885-90
17108125
Thromb Haemost. 2007 Mar;97(3):336-42
17334498
J Clin Oncol. 2007 Feb 1;25(4):349-55
17264329
Tumori. 2008 Jul-Aug;94(4):505-10
18822686
J Thromb Haemost. 2010 Dec;8(12):2789-99
20880257
Nat Rev Cancer. 2010 Jul;10(7):481-8
20535132
J Biol Chem. 2005 Jul 1;280(26):25225-32
15866865
FEBS Lett. 1994 Aug 1;349(2):163-8
8050560
Cancer Res. 1987 Jun 15;47(12):3239-45
2438036
Cancer Res. 1999 Oct 15;59(20):5307-14
10537314
Clin Biochem. 2004 Jul;37(7):541-8
15234235
Trends Immunol. 2004 Aug;25(8):450-5
15275645
Cancer Res. 1994 Oct 15;54(20):5445-54
7923178
Blood. 2005 Mar 1;105(5):2198-205
15494432
J Bone Joint Surg Am. 2009 May;91(5):1063-72
19411454
Br J Cancer. 2010 Feb 16;102(4):731-7
20051950
Arterioscler Thromb Vasc Biol. 2001 Jul;21(7):1104-17
11451738
Cell Mol Life Sci. 2011 Jul;68(14):2453-67
20972812
Trends Biotechnol. 2007 Jan;25(1):33-9
17084931
Cancer Metastasis Rev. 2003 Jun-Sep;22(2-3):205-22
12784997
Proc Natl Acad Sci U S A. 2002 Feb 5;99(3):1359-64
11818541
Hum Pathol. 2000 Mar;31(3):341-6
10746677